Company news
Immunome, Inc. (NASDAQ:IMNM) news
Immunome, Inc. news releases on 6ix. Latest, Oct 6, 2026: Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releases & updates
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 6, 2026
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
September 30, 2026
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 2, 2026
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
July 20, 2026
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
July 8, 2026
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
June 11, 2026
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
May 29, 2026
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
April 29, 2026
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
April 20, 2026
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
March 3, 2026
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 4, 2026
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 3, 2026
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Immunome Announces Pricing of Public Offering of Common Stock
December 15, 2025
Immunome Announces Proposed Public Offering of Common Stock
December 14, 2025
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
December 14, 2025
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
December 13, 2025
Immunome to Present at Upcoming Investor Conferences
November 24, 2025
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update
November 5, 2025
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference
October 30, 2025
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
October 22, 2025
Infinimmune Announces Research Collaboration with Immunome
September 18, 2025
Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update
August 6, 2025
Immunome to Present at Upcoming Investor Conferences
May 21, 2025
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update
May 11, 2025
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference
April 3, 2025
Immunome Reports Full Year 2024 Financial Results and Provides Business Update
March 18, 2025
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
March 9, 2025
Immunome to Present at Upcoming March Conferences
February 24, 2025
Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer
February 10, 2025
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 30, 2025
Immunome Announces Pricing of Upsized Public Offering of Common Stock
January 28, 2025
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
January 12, 2025
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
January 6, 2025
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
November 4, 2024
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
October 28, 2024
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
October 17, 2024
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
October 7, 2024
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
September 12, 2024
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 28, 2024
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
August 11, 2024
Nectin Therapeutics Licenses Novel Antibodies to Immunome
July 24, 2024
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
July 24, 2024
Immunome Appoints Phil Tsai as Chief Technical Officer
June 26, 2024